Compounds > osu-2s
Page last updated: 2024-11-13

osu-2s

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

OSU-2S: a nonimmunosuppressive analog of FTY720 with antitumor effects; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53234284
CHEMBL ID4171193
SCHEMBL ID8510221
MeSH IDM0560441

Synonyms (7)

Synonym
SCHEMBL8510221
1351056-65-9
(s)-2-amino-2-(4-[(6-methylheptyl)-oxy]phenethyl)pentan-1-ol
CHEMBL4171193
HY-117720
osu-2s
CS-0067023
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1501707Cell cycle arrest in human HepG2 cells assessed as accumulation at G1 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 40.4%)2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501704Inhibition of Akt Ser473 phosphorylation in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501706Cell cycle arrest in human HepG2 cells assessed as accumulation at sub G1 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 3%)2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501708Cell cycle arrest in human HepG2 cells assessed as accumulation at S phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 24.24%)2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501700Induction of PKCdelta cleavage in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501701Inhibition of Akt Ser473 phosphorylation in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501696Cytotoxicity against human A549 cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501705Inhibition of ERK1/2 phosphorylation in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501709Cell cycle arrest in human HepG2 cells assessed as accumulation at G2/M phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 25.6%)2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501698Cytotoxicity against human F180 cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501710Cell cycle arrest in human Hep3B p53-deficient cells at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501703Induction of PKCdelta cleavage in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501695Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501697Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501717Inhibition of Akt Thr408 phosphorylation in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501694Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501699Induction of apoptosis in human Hep3B cells assessed as increase in caspase3/7 activity at 5 uM after 24 to 48 hrs by Caspase-Glo 3/7 assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501716Inhibition of Akt Thr408 phosphorylation in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501702Inhibition of ERK1/2 phosphorylation in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.48 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fingolimod hydrochloride
Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.. fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).		3.0340hydrochlorideimmunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
sorafenib
[no description available]		2.1510(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
sphingosine
sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.		3.3960sphing-4-eninehuman metabolite;
mouse metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatocellular Carcinoma
[description not available]		07.520
Cancer of Liver
[description not available]		02.520
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.520
Liver Neoplasms
Tumors or cancer of the LIVER.		02.520
Acute Lymphoid Leukemia
[description not available]		02.4110
African Lymphoma
[description not available]		02.4110
Chromosomal Translocation
[description not available]		02.4110
Burkitt Lymphoma
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.		02.4110
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		02.4110
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
[description not available]		02.1110
Lymphoma, Mantle-Cell
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).		02.1110
Canine Diseases
[description not available]		02.1510
B-Cell Lymphoma
[description not available]		07.1510
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		02.1510